Aclaris Therapeutics Inc ACRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.71
- Day Range
- $5.46–5.76
- 52-Week Range
- $1.46–5.85
- Bid/Ask
- $5.56 / $5.85
- Shares Outstanding
- 139.66M
- Market Cap
- $779.32M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 83.40
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- https://www.aclaristx.com
Valuation
|
Metric
|
ACRS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.46 |
Price/Sales | 83.40 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACRS
|
|---|---|
Quick Ratio | 3.85 |
Current Ratio | 4.03 |
Interest Coverage | — |
Quick Ratio
ACRS
Profitability
|
Metric
|
ACRS
|
|---|---|
Return on Assets (Normalized) | −30.16% |
Return on Equity (Normalized) | −43.27% |
Return on Invested Capital (Normalized) | −48.71% |
Return on Assets
ACRS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|L<%b>? | LOCK|&M^T | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|n$#pSv | LOCK|mWh> | $70B | |||
| argenx SE ADR
ARGX
| LOCK|TZzm&? | LOCK|Jk@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^?b#<n | LOCK|SYWdh | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^LLm<> | LOCK|s$ | $36B | |||
| Moderna Inc
MRNA
| LOCK|&dP>># | LOCK|#Ry | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@L$r^S? | LOCK|C$WbS | $25B | |||
| Incyte Corp
INCY
| LOCK|y&L#rv | LOCK|&!S | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?N>kCly | LOCK|cK | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|gPsLW$P | LOCK|$Q% | $17B |
United States